Parsa Kiai Purchases 29,337 Shares of Medifast (NYSE:MED) Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai acquired 29,337 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was acquired at an average price of $11.66 per share, for a total transaction of $342,069.42. Following the transaction, the director directly owned 619,331 shares of the company’s stock, valued at $7,221,399.46. This represents a 4.97% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Parsa Kiai also recently made the following trade(s):

• On Thursday, August 20th, Parsa Kiai acquired 43,150 shares of Medifast stock. The shares were acquired at an average cost of $11.60 per share, with a total value of $500,540.00.

Medifast Stock Up 3.3%

Medifast stock opened at $12.00 on Friday. Medifast Inc has a 52 week low of $9.22 and a 52 week high of $14.67. The business has a 50-day simple moving average of $10.92 and a 200 day simple moving average of $11.06. The stock has a market cap of $134.16 million, a price-to-earnings ratio of -5.15 and a beta of 0.65.

Medifast (NYSE:MED) last announced its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.The business had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, research analysts anticipate that Medifast Inc will post -1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Zacks Research lowered shares of Medifast from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $12.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in Medifast by 103.1% during the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after purchasing an additional 1,187 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Medifast during the 3rd quarter valued at about $37,000. Intesa Sanpaolo Wealth Management purchased a new position in shares of Medifast during the 4th quarter valued at about $47,000. State of Wyoming bought a new stake in Medifast in the 4th quarter worth approximately $59,000. Finally, Ancora Advisors LLC bought a new stake in Medifast in the 2nd quarter worth approximately $75,000. Institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.